Modern Covid Vaccine cleared in America for children between 6 months to 11 years of age
Modern’s spikewax was earlier available to the pediatric population under the Emergency Use Authority. Modern hopes that 2025–26 will provide their update vaccine for a qualified American population for the season of respiratory virus.

In short
- FDA gives complete approval to modern spikewax vaccine
- The vaccine should be used for children from 6 months to 11 years at risk
- The first is available only under the Emergency Use Authority
The US Food and Drug Administration has given full approval for modern MRNA.O Kovid -19 vaccine, spikewax in children aged 11 years of age in children aged 11 years, which increase the risk of disease, the company said on Thursday.
The shot was earlier available to the pediatric population under the Emergency Use Authority. Modern hopes that 2025–26 will provide their update vaccine for a qualified American population for the season of respiratory virus.
Health Secretary Robert F. Kennedy Junior said in May that the US has stopped recommending regular Kovid -19 vaccination for healthy children and healthy pregnant women.
However, the US Center for Disease Control and Prevention said that shots are an alternative to healthy children when parents and doctors agree that it is needed.
The agency recommended Kovid vaccines updated to all people aged six months and above after the guidance of its panel of external experts.
Kennedy, who has been doubted about the safety of vaccines by scientists for decades, oversees the CDC.
They have been sued by several major medical organizations, arguing that the current policies on the Covid-19 vaccine pose a adjacent threat to public health.
In addition to the instructions on Covid vaccines, Kennedy fired all 17 members of the CDC advisory committee on vaccination practices, the independent panels of experts who recommend on the vaccine policy, and replaced them with seven new members, including many who have advocated against vaccines.
The company’s shares rose 2 percent to US $ 33.45 in premarket trading.